HemoShear Therapeutics

LifeMine Therapeutics combines genomics with AI and synthetic biology to discover and develop a pipeline of novel medicines. LifeMine’s Avatar-Rx platform integrates high-throughput microbiology, data science and machine learning, genome engineering, and automation technologies to search the fungal biosphere for novel GEMs having a predetermined target and biological function. The platform integrates chemoinformatic-assisted drug optimization and state-of-the-art chemical synthesis with biotransformation to advance new product candidates into development. Founded by Gregory Verdine, PhD, Rick Klausner, MD, and WeiQing Zhou, MBA. LifeMine Therapeutics is headquartered in Cambridge, Massachusetts.

Metaphore Biotechnologies use biomimicry and machine learning to unveil the revolutionary medicinal potential of functional molecular mimics. The MIMiCTM platform, developed by the business, is a computationally driven bio platform for developing novel therapies in which function, specificity, and selectivity may be optimized. Metaphore is dedicated to uncovering previously inaccessible pharmacological targets and achieving breakthroughs that exceed today's medications for maximum patient effect.

BRAINBox provides objective evidence of injury and prediction of patient recovery. BRAINBox Solutions' multi-modality approach is led by the leaders in the industry. It includes blood biomarker panels available on a point of care instrument and standard laboratory systems.

CND Life Sciences is committed to supporting patients with neurodegenerative diseases, offering the Syn-One Test® as a first-of-its-kind tool to detect and measure misfolded phosphorylated alpha-synuclein in cutaneous nerve fibers. This test helps confirm synucleinopathies like Parkinson's disease, dementia with Lewy bodies, multiple system atrophy, and pure autonomic failure. The company operates a CLIA-certified and CAP-accredited lab in Scottsdale, AZ, providing a convenient and accurate alternative for diagnosis through skin biopsies. Additionally, CND collaborates with biopharmaceutical companies to advance research in the field.

Dash Bio is a cutting-edge platform that employs AI, robotics, and fully integrated software to revolutionize the process of drug development and bring new medications to market.

Genomenon develops software tools to rapidly and autonomously prioritize data points for decision-making. It revolutionizes the way genetic diagnoses and discoveries are made. The company’s suite of diagnostic and discovery tools enable physicians, pharma, and researchers to quickly and accurately identify disease-causing variants from genomic-sequencing datasets. It was founded in 2014 and is headquartered in Ann Arbor, Michigan.

Adjuvia Therapeutics is a clinical-stage biopharmaceutical company.

CoreMap exists to improve patient outcomes by delivering advanced diagnostic technology to electrophysiologists and patients.

Sonavex, Inc. is a Baltimore-based medical device company originally spun out of Johns Hopkins focused on Empowered Patient Care. The company has developed a portfolio of novel ultrasound solutions that empower patient care by delivering critical visual and quantitative data to improve outcomes and reduce costs. EchoMark is a bioresorbable and highly echogenic (visible under ultrasound) implant used to mark at-risk blood vessels such that the site can be easily assessed for future complications. EchoSure is a deep-learning enabled 3D automated ultrasound device designed to be used by healthcare providers without ultrasound training to assess blood flow and morphology of vessels marked by the implanted EchoMark device. For more information, please visit http://www.sonavex.com

ALZpath is a biotech organization that offers innovative diagnostic options for Alzheimer's disease.

Reme-D is a cutting-edge technology company that has patented technology, which is revolutionizing healthcare in areas with limited resources by providing cost-effective and efficient disease testing systems. This ensures that everyone has equal access to essential medical diagnostics.

Trellis Bioscience develops a technology platform for cellular informatics. The company's technology has applications in the discovery and production of therapeutic monoclonal antibodies. Its cell biology platform provides a direct readout at the single cell level for monitoring activity of diverse cell types and quantifying the impact of potential therapeutic interventions. The company is based in San Francisco, California.